--12-31false0001850906Q30001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001850906us-gaap:RetainedEarningsMember2024-06-300001850906omic:InstrumentsAtCustomerSiteMember2023-12-310001850906us-gaap:AdditionalPaidInCapitalMember2024-06-300001850906omic:DeerfieldHolderMember2022-01-012022-01-310001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001850906us-gaap:RetainedEarningsMember2024-04-012024-06-300001850906us-gaap:RetainedEarningsMember2023-03-310001850906omic:TwoThousandNineteenSiliconValleyBankLoanMember2019-11-012019-11-300001850906omic:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2023-09-300001850906us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:EquipmentMember2023-12-310001850906us-gaap:EmployeeStockMember2023-01-012023-09-300001850906us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001850906us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906omic:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2024-09-300001850906us-gaap:EmployeeStockMember2024-01-012024-09-300001850906us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906omic:TwoBuildingsMember2022-01-310001850906us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:RetainedEarningsMember2024-01-012024-03-310001850906us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906omic:SeriesAConvertiblePreferredStockMember2023-12-310001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001850906us-gaap:FurnitureAndFixturesMember2024-09-300001850906omic:SecondTrancheMember2021-09-300001850906us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001850906us-gaap:CommonStockMember2023-04-012023-06-300001850906us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-3000018509062022-01-310001850906us-gaap:RetainedEarningsMember2024-09-300001850906omic:LoanAndSecurityAgreementMemberomic:SiliconValleyBankWarrantMember2020-03-310001850906us-gaap:CommonStockMember2023-06-300001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001850906us-gaap:EmployeeSeveranceMember2024-01-012024-09-300001850906us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906omic:InstrumentsAtCustomerSiteMember2024-01-012024-09-300001850906us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001850906omic:TwoThousandTwentyOneSiliconValleyBankLoanMember2024-09-300001850906omic:DeerfieldHolderMemberomic:SeriesAConvertiblePreferredStockMember2022-01-310001850906us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906us-gaap:SeriesAPreferredStockMember2024-06-250001850906us-gaap:SalesRevenueNetMemberomic:ThreeCustomersMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001850906srt:MinimumMemberomic:TwoThousandTwentyOnePlanMember2024-01-012024-09-300001850906us-gaap:AdditionalPaidInCapitalMember2024-03-310001850906omic:TwoBuildingsMember2022-01-012022-03-310001850906us-gaap:CommonStockMember2024-07-012024-09-3000018509062024-07-012024-09-3000018509062022-12-310001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001850906srt:MinimumMember2023-01-012023-09-3000018509062023-01-012023-09-300001850906us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:PreferredStockMember2023-03-310001850906us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:RetainedEarningsMember2022-12-310001850906us-gaap:FairValueInputsLevel1Memberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906us-gaap:AdditionalPaidInCapitalMember2022-12-3100018509062024-01-012024-09-3000018509062024-06-250001850906omic:LeaseAgreementMember2020-06-012020-06-300001850906us-gaap:CommonStockMember2023-01-012023-03-3100018509062024-04-012024-06-3000018509062024-03-310001850906us-gaap:PreferredStockMember2024-03-310001850906omic:ComputersAndSoftwareMember2024-09-300001850906us-gaap:LeaseholdImprovementsMember2024-01-012024-09-300001850906us-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001850906us-gaap:CorporateDebtSecuritiesMember2023-12-310001850906us-gaap:USTreasurySecuritiesMember2024-09-300001850906us-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906us-gaap:ConvertiblePreferredStockMemberomic:DeerfieldHolderMember2022-01-310001850906us-gaap:USTreasurySecuritiesMember2023-12-310001850906omic:LoanAndSecurityAgreementMember2019-11-300001850906us-gaap:PreferredStockMember2024-06-300001850906us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906omic:AlexandriaRealEstateEquitiesMember2024-08-020001850906us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-3000018509062023-04-012023-06-300001850906us-gaap:AdditionalPaidInCapitalMember2024-09-300001850906omic:TwoThousandNineteenSiliconValleyBankLoanMember2024-01-012024-09-300001850906us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906us-gaap:RetainedEarningsMember2023-12-310001850906us-gaap:EquipmentMember2024-09-300001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001850906omic:LicenseAgreementMember2023-01-012023-09-3000018509062024-01-012024-03-310001850906omic:InstrumentsAtCustomerSiteMember2024-09-300001850906us-gaap:FurnitureAndFixturesMember2024-01-012024-09-300001850906us-gaap:CommonStockMember2024-09-300001850906us-gaap:LeaseholdImprovementsMember2024-09-3000018509062023-01-012023-03-310001850906omic:TwoThousandTwentyOneSiliconValleyBankLoanMember2022-09-012022-09-300001850906us-gaap:RetainedEarningsMember2024-03-310001850906us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001850906us-gaap:CommonStockMember2024-06-300001850906us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001850906us-gaap:AdditionalPaidInCapitalMember2023-12-310001850906us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906omic:ComputersAndSoftwareMember2023-12-310001850906us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906us-gaap:AdditionalPaidInCapitalMember2023-03-310001850906omic:TwoThousandTwentyOnePlanMember2024-09-300001850906us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:EmployeeSeveranceMember2024-03-142024-03-140001850906us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001850906us-gaap:CashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001850906us-gaap:RetainedEarningsMember2023-04-012023-06-300001850906us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001850906omic:SeriesAConvertiblePreferredStockMember2024-09-300001850906us-gaap:RestrictedStockMember2024-01-012024-09-300001850906us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001850906us-gaap:GeneralAndAdministrativeExpenseMemberus-gaap:EmployeeSeveranceMember2024-01-012024-09-3000018509062022-01-012022-01-310001850906us-gaap:CashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001850906omic:SiliconValleyBankWarrantMember2021-09-300001850906us-gaap:FurnitureAndFixturesMember2023-12-310001850906us-gaap:ConvertiblePreferredStockMember2024-01-012024-09-300001850906us-gaap:RestrictedStockMember2023-12-3100018509062023-12-310001850906omic:AlexandriaRealEstateEquitiesMember2024-07-012024-09-300001850906us-gaap:LeaseholdImprovementsMember2023-12-310001850906omic:ConsumablesAndServiceMember2024-01-012024-09-300001850906us-gaap:CommonStockMember2024-03-310001850906omic:LeaseMember2024-09-300001850906us-gaap:CommonStockMember2023-03-310001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001850906us-gaap:RetainedEarningsMember2024-07-012024-09-3000018509062023-06-300001850906omic:LoanAndSecurityAgreementMember2021-09-300001850906us-gaap:RetainedEarningsMember2023-09-300001850906us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001850906us-gaap:CommonStockMember2024-01-012024-03-310001850906us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:RetainedEarningsMember2023-01-012023-03-310001850906us-gaap:ConvertiblePreferredStockMember2023-01-012023-09-300001850906us-gaap:CommonStockMember2023-09-300001850906omic:CommonStockSubjectToTheCompanysRightOfRepurchaseMember2024-01-012024-09-300001850906omic:AuthorizeForFutureOptionsGrantsMemberomic:TwoThousandTwentyOnePlanMember2024-09-300001850906omic:LicenseAgreementMember2024-01-012024-09-300001850906omic:AuthorizedForIssuanceUnderTheEsppPlanMemberomic:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2024-01-012024-09-300001850906us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906omic:InstrumentsMember2024-01-012024-09-300001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001850906srt:MaximumMember2023-01-012023-09-300001850906omic:FirstTranchesMember2021-09-300001850906omic:CommonStockSubjectToTheCompanysRightOfRepurchaseMember2023-01-012023-09-3000018509062023-09-300001850906us-gaap:EmployeeSeveranceMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001850906us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906us-gaap:PreferredStockMember2023-12-310001850906omic:LicenseAgreementMember2024-09-300001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001850906us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001850906omic:LeaseMember2019-11-012019-11-300001850906us-gaap:RetainedEarningsMember2023-06-300001850906us-gaap:PreferredStockMember2022-12-3100018509062024-10-310001850906us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906us-gaap:AssetBackedSecuritiesMember2023-12-310001850906us-gaap:RestrictedStockMember2024-09-300001850906us-gaap:EmployeeStockOptionMember2024-09-300001850906omic:TwoThousandTwentyOneSiliconValleyBankLoanMember2022-09-300001850906us-gaap:AdditionalPaidInCapitalMember2023-06-300001850906us-gaap:PreferredStockMember2024-09-300001850906us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001850906us-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001850906omic:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2024-01-012024-09-300001850906us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001850906us-gaap:CommonStockMember2024-04-012024-06-300001850906us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001850906us-gaap:CommonStockMember2023-07-012023-09-3000018509062023-03-310001850906us-gaap:RetainedEarningsMember2023-07-012023-09-300001850906us-gaap:CommonStockMember2023-12-310001850906us-gaap:PreferredStockMember2023-09-300001850906us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001850906us-gaap:PreferredStockMember2023-06-3000018509062024-06-300001850906us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001850906us-gaap:AdditionalPaidInCapitalMember2023-09-300001850906us-gaap:ConvertiblePreferredStockMember2022-01-310001850906us-gaap:CommonStockMember2022-12-3100018509062023-07-012023-09-3000018509062024-09-30xbrli:purexbrli:sharesomic:Segmentiso4217:USD
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to .
Commission File Number: 001-40443
Singular Genomics Systems, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware |
|
81-2948451 |
(State or other jurisdiction of
incorporation or organization) |
|
(I.R.S. Employer
Identification Number) |
|
3010 Science Park Road
San Diego, California 92121 |
(858) 333-7830
(Registrant’s address of principal executive offices
and telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class |
Trading Symbol |
Name of each exchange on which registered |
Common Stock, $0.0001 par value per share |
OMIC |
Nasdaq Capital Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
Large accelerated filer |
☐ |
|
Accelerated filer |
☐ |
Non-accelerated filer |
☒ |
|
Smaller reporting company |
☒ |
|
|
|
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
There were 2,511,783 shares of common stock, $0.0001 par value, outstanding as of October 31, 2024.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This filing contains forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, future revenue, business strategy, prospects, products, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
The words “anticipate,” “believe,” contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or “would” or the negative of these terms or other similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this report include, but are not limited to, statements about:
•the outcome of our strategic alternative process;
•estimates of our addressable market, market growth, future revenue, expenses, capital requirements and our needs for additional financing;
•our ability to timely and successfully complete the development and implement our commercialization plans for the G4X, spatial biology services, and our product pipeline;
•the implementation of our business model and strategic plans for the G4X, our spatial biology service offerings, and our product pipeline;
•our expectations regarding the rate and degree of market acceptance of the G4X, our spatial biology service offerings, and our product pipeline;
•our ability to compete with competitive companies and technologies in our industry;
•our ability to manage and grow our business and commercialize the G4X, our spatial biology service offerings, and our product pipeline;
•our ability to develop and commercialize new products and product enhancements;
•the impact of downward macroeconomic pressures on our business;
•our ability to establish and maintain intellectual property protection for our products or avoid or defend claims of infringement;
•our ability to fulfill our contractual commitments;
•the performance of third-party manufacturers and suppliers;
•our ability to effectively manufacture our products;
•the potential effects of government regulation;
•our ability to hire and retain key personnel and to manage our future growth effectively;
•our ability to obtain additional financing on favorable terms to us or at all;
•the impact of local, regional, national and international economic conditions and events;
•our expectations about market trends; and
•our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section titled “Risk Factors” elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely on forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, advancements, discoveries, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.
You should read this report and the documents that we reference in this report and have filed with the Securities and Exchange Commission as exhibits to this report with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.
Summary of Material Risks Associated with Our Business
Our business is subject to a number of risks that if realized could materially affect our business, prospects, operating results and financial condition. These risks are discussed more fully in the “Risk Factors” section elsewhere in this report. These risks include the following:
•We may not identify or enter into a strategic transaction, which could have an adverse effect on our stock price and our business.
•Our limited operating history makes it difficult to evaluate our future prospects and the risks and challenges we may encounter.
•We have incurred significant losses since inception, we expect to incur significant losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability.
•We have only recently generated revenue and have very limited history in developing and commercializing our products or technology, which makes it difficult to evaluate our prospects and predict our future performance.
•The life sciences technology market is highly competitive. If we fail to compete effectively, our business and operating results will suffer.
•If we are sued for infringing, misappropriating or otherwise violating intellectual property rights of third parties, such litigation could be costly and time-consuming and could prevent or delay us from developing or commercializing our products.
•We could have disputes with contractual counterparties regarding our or their performance under those contracts, we could be unable to fulfill such contractual commitments, or our contractual obligations may exceed our current expectations.
•If our products fail to achieve early customer and scientific acceptance, we may not be able to achieve broader market acceptance for our products, and our revenues and prospects may be harmed.
•We expect to be highly dependent upon revenue generated from the sale of G4 consumables, the G4X, our spatial biology service offerings, and future products, and any delay or failure by us to successfully develop and commercialize the G4X, our spatial biology service offerings, or other future products could have a substantial adverse effect on our business and results of operations.
•Our business will depend significantly on research and development spending by academic institutions and other research institutions, and any reduction in spending could limit demand for our products and adversely affect our business, results of operations, financial condition and prospects.
•Our operating results may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.
•We have only launched one commercial product, the G4, and we may not be able to successfully develop or commercially launch the G4X, our spatial biology service offerings, or any other products as planned.
•The G4 is, and the G4X and any associated spatial biology services will be, sold as research-use-only products or services, as applicable; changes in the regulatory landscape could affect the market for such products and services.
•If we are unable to obtain and maintain sufficient intellectual property protection for our products and technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be impaired.
•We may require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back or cease our product development programs or operations.
Trademarks and Trade Names
Singular Genomics®, G4®, G4X and our other logos and trademarks are the property of Singular Genomics Systems, Inc. All other brand names or trademarks appearing in this report are the property of their respective holders. Our use or display of other parties’ trademarks, trade dress or products in this report does not imply that we have a relationship with, or the endorsement or sponsorship of, the trademark or trade dress owners.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Singular Genomics Systems, Inc.
Balance Sheets
(In thousands, except share and par value amounts)
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2024 |
|
|
2023 |
|
|
|
(Unaudited) |
|
|
|
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
52,620 |
|
|
$ |
16,233 |
|
Short-term investments |
|
|
61,213 |
|
|
|
157,708 |
|
Accounts receivable |
|
|
183 |
|
|
|
565 |
|
Inventory, net |
|
|
12,410 |
|
|
|
13,572 |
|
Prepaid expenses and other current assets |
|
|
3,384 |
|
|
|
4,150 |
|
Total current assets |
|
|
129,810 |
|
|
|
192,228 |
|
Right-of-use lease assets |
|
|
42,617 |
|
|
|
57,797 |
|
Property and equipment, net |
|
|
12,457 |
|
|
|
13,692 |
|
Restricted cash |
|
|
600 |
|
|
|
600 |
|
Other noncurrent assets |
|
|
1,067 |
|
|
|
1,150 |
|
Total assets |
|
$ |
186,551 |
|
|
$ |
265,467 |
|
|
|
|
|
|
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
1,882 |
|
|
$ |
2,587 |
|
Accrued expenses |
|
|
4,887 |
|
|
|
6,079 |
|
Lease liabilities, current |
|
|
5,469 |
|
|
|
7,764 |
|
Other current liabilities |
|
|
5,371 |
|
|
|
1,857 |
|
Total current liabilities |
|
|
17,609 |
|
|
|
18,287 |
|
Lease liabilities, noncurrent |
|
|
39,857 |
|
|
|
58,623 |
|
Long-term debt, net of issuance costs |
|
|
5,166 |
|
|
|
8,901 |
|
Other noncurrent liabilities |
|
|
666 |
|
|
|
650 |
|
Total liabilities |
|
|
63,298 |
|
|
|
86,461 |
|
Commitments and contingencies (Note 9) |
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
Series A common stock equivalent convertible preferred stock, $0.0001 par value; 7,000 shares authorized, 2,500 shares issued and outstanding at September 30, 2024 and December 31, 2023 |
|
|
- |
|
|
|
- |
|
Common stock, $0.0001 par value; 400,000,000 shares authorized, 2,507,171 and 2,460,772 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively |
|
|
- |
|
|
|
7 |
|
Additional paid-in capital |
|
|
523,838 |
|
|
|
516,439 |
|
Accumulated other comprehensive gain |
|
|
83 |
|
|
|
155 |
|
Accumulated deficit |
|
|
(400,668 |
) |
|
|
(337,595 |
) |
Total stockholders’ equity |
|
|
123,253 |
|
|
|
179,006 |
|
Total liabilities and stockholders’ equity |
|
$ |
186,551 |
|
|
$ |
265,467 |
|
See accompanying notes to these unaudited financial statements.
Singular Genomics Systems, Inc.
Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
Revenue |
$ |
406 |
|
|
$ |
462 |
|
|
$ |
1,586 |
|
|
$ |
1,830 |
|
Cost of revenue |
|
707 |
|
|
|
527 |
|
|
|
2,483 |
|
|
|
1,931 |
|
Gross margin |
|
(301 |
) |
|
|
(65 |
) |
|
|
(897 |
) |
|
|
(101 |
) |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
9,568 |
|
|
|
11,220 |
|
|
|
31,790 |
|
|
|
36,074 |
|
Selling, general and administrative |
|
8,202 |
|
|
|
13,254 |
|
|
|
35,036 |
|
|
|
41,345 |
|
Total operating expenses |
|
17,770 |
|
|
|
24,474 |
|
|
|
66,826 |
|
|
|
77,419 |
|
Loss from operations |
|
(18,071 |
) |
|
|
(24,539 |
) |
|
|
(67,723 |
) |
|
|
(77,520 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
1,562 |
|
|
|
2,464 |
|
|
|
5,506 |
|
|
|
6,763 |
|
Interest expense |
|
(286 |
) |
|
|
(285 |
) |
|
|
(856 |
) |
|
|
(814 |
) |
Total other income |
|
1,276 |
|
|
|
2,179 |
|
|
|
4,650 |
|
|
|
5,949 |
|
Net loss |
$ |
(16,795 |
) |
|
$ |
(22,360 |
) |
|
$ |
(63,073 |
) |
|
$ |
(71,571 |
) |
Net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share |
$ |
(6.72 |
) |
|
$ |
(9.25 |
) |
|
$ |
(25.41 |
) |
|
$ |
(29.73 |
) |
Weighted-average shares used to compute basic and diluted net loss per share |
|
2,501,093 |
|
|
|
2,417,001 |
|
|
|
2,481,956 |
|
|
|
2,407,276 |
|
See accompanying notes to these unaudited financial statements.
Singular Genomics Systems, Inc.
Statements of Comprehensive Loss
(Unaudited)
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
2024 |
|
|
2023 |
|
|
2024 |
|
|
2023 |
|
Net loss |
$ |
(16,795 |
) |
|
$ |
(22,360 |
) |
|
$ |
(63,073 |
) |
|
$ |
(71,571 |
) |
Other comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
Unrealized gain (loss) on available-for-sale securities |
|
157 |
|
|
|
114 |
|
|
|
(72 |
) |
|
|
623 |
|
Comprehensive loss |
$ |
(16,638 |
) |
|
$ |
(22,246 |
) |
|
$ |
(63,145 |
) |
|
$ |
(70,948 |
) |
See accompanying notes to these unaudited financial statements.
Singular Genomics Systems, Inc.
Statements of Preferred Stock and Stockholders’ Equity
(Unaudited)
(In thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock |
|
|
Common Stock |
|
|
Additional
Paid-In |
|
|
Accumulated
Other
Comprehensive |
|
|
Accumulated |
|
|
Total
Stockholders’ |
|
|
Shares |
|
Amount |
|
|
Shares |
|
Amount |
|
|
Capital |
|
|
Gain (Loss) |
|
|
Deficit |
|
|
Equity |
|
Balance at December 31, 2023 |
|
2,500 |
|
|
- |
|
|
|
2,460,772 |
|
|
7 |
|
|
|
516,439 |
|
|
|
155 |
|
|
|
(337,595 |
) |
|
|
179,006 |
|
Vesting of common stock issued for early exercise of stock options |
|
- |
|
|
- |
|
|
|
542 |
|
|
- |
|
|
|
26 |
|
|
|
- |
|
|
|
- |
|
|
|
26 |
|
Issuance of common stock in connection with vesting of restricted stock units |
|
- |
|
|
- |
|
|
|
7,598 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Stock-based compensation |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
2,896 |
|
|
|
- |
|
|
|
- |
|
|
|
2,896 |
|
Unrealized loss on available-for-sale securities |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
(206 |
) |
|
|
- |
|
|
|
(206 |
) |
Net loss |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(25,024 |
) |
|
|
(25,024 |
) |
Balance at March 31, 2024 |
|
2,500 |
|
|
- |
|
|
|
2,468,912 |
|
|
7 |
|
|
|
519,361 |
|
|
|
(51 |
) |
|
|
(362,619 |
) |
|
|
156,698 |
|
Vesting of common stock issued for early exercise of stock options |
|
- |
|
|
- |
|
|
|
261 |
|
|
- |
|
|
|
20 |
|
|
|
- |
|
|
|
- |
|
|
|
20 |
|
Issuance of common stock in connection with vesting of restricted stock units |
|
- |
|
|
- |
|
|
|
14,200 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Issuance of common stock in connection with employee stock purchase plan |
|
- |
|
|
- |
|
|
|
8,208 |
|
|
- |
|
|
|
80 |
|
|
|
- |
|
|
|
- |
|
|
|
80 |
|
Reverse stock split adjustments |
|
- |
|
|
- |
|
|
|
38 |
|
|
(7 |
) |
|
|
7 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Stock-based compensation |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
2,186 |
|
|
|
- |
|
|
|
- |
|
|
|
2,186 |
|
Unrealized loss on available-for-sale securities |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
(23 |
) |
|
|
- |
|
|
|
(23 |
) |
Net loss |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(21,254 |
) |
|
|
(21,254 |
) |
Balance at June 30, 2024 |
|
2,500 |
|
|
- |
|
|
|
2,491,619 |
|
|
- |
|
|
|
521,654 |
|
|
|
(74 |
) |
|
|
(383,873 |
) |
|
|
137,707 |
|
Vesting of common stock issued for early exercise of stock options |
|
- |
|
|
- |
|
|
|
150 |
|
|
- |
|
|
|
19 |
|
|
|
- |
|
|
|
- |
|
|
|
19 |
|
Issuance of common stock in connection with vesting of restricted stock units |
|
- |
|
|
- |
|
|
|
15,402 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Stock-based compensation |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
2,165 |
|
|
|
- |
|
|
|
- |
|
|
|
2,165 |
|
Unrealized gain on available-for-sale marketable securities |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
157 |
|
|
|
- |
|
|
|
157 |
|
Net loss |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(16,795 |
) |
|
|
(16,795 |
) |
Balance at September 30, 2024 |
|
2,500 |
|
|
- |
|
|
|
2,507,171 |
|
|
- |
|
|
|
523,838 |
|
|
|
83 |
|
|
|
(400,668 |
) |
|
|
123,253 |
|
Singular Genomics Systems, Inc.
Statements of Preferred Stock and Stockholders’ Equity (continued)
(Unaudited)
(In thousands, except share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred Stock |
|
|
Common Stock |
|
|
Additional
Paid-In |
|
|
Accumulated
Other
Comprehensive |
|
|
Accumulated |
|
|
Total
Stockholders’ |
|
|
Shares |
|
Amount |
|
|
Shares |
|
Amount |
|
|
Capital |
|
|
Loss |
|
|
Deficit |
|
|
Equity |
|
Balance at December 31, 2022 |
|
2,500 |
|
$ |
- |
|
|
|
2,395,157 |
|
$ |
7 |
|
|
$ |
503,926 |
|
|
$ |
(837 |
) |
|
$ |
(242,775 |
) |
|
$ |
260,321 |
|
Vesting of common stock issued for early exercise of stock options |
|
- |
|
|
- |
|
|
|
4,060 |
|
|
- |
|
|
|
97 |
|
|
|
- |
|
|
|
- |
|
|
|
97 |
|
Issuance of common stock in connection with exercise of stock options |
|
- |
|
|
- |
|
|
|
649 |
|
|
- |
|
|
|
13 |
|
|
|
- |
|
|
|
- |
|
|
|
13 |
|
Stock-based compensation |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
3,081 |
|
|
|
- |
|
|
|
- |
|
|
|
3,081 |
|
Unrealized gain on available-for-sale securities |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
446 |
|
|
|
- |
|
|
|
446 |
|
Net loss |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(23,633 |
) |
|
|
(23,633 |
) |
Balance at March 31, 2023 |
|
2,500 |
|
$ |
- |
|
|
|
2,399,866 |
|
$ |
7 |
|
|
$ |
507,117 |
|
|
$ |
(391 |
) |
|
$ |
(266,408 |
) |
|
$ |
240,325 |
|
Vesting of common stock issued for early exercise of stock options |
|
- |
|
|
- |
|
|
|
3,963 |
|
|
- |
|
|
|
112 |
|
|
|
- |
|
|
|
- |
|
|
|
112 |
|
Issuance of common stock in connection with exercise of stock options |
|
- |
|
|
- |
|
|
|
110 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Issuance of common stock in connection with vesting of restricted stock units |
|
- |
|
|
- |
|
|
|
4,697 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Issuance of common stock in connection with employee stock purchase plan |
|
- |
|
|
- |
|
|
|
27,514 |
|
|
- |
|
|
|
624 |
|
|
|
- |
|
|
|
- |
|
|
|
624 |
|
Stock-based compensation |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
2,842 |
|
|
|
- |
|
|
|
- |
|
|
|
2,842 |
|
Unrealized gain on available-for-sale securities |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
63 |
|
|
|
- |
|
|
|
63 |
|
Net loss |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(25,578 |
) |
|
|
(25,578 |
) |
Balance at June 30, 2023 |
|
2,500 |
|
$ |
- |
|
|
|
2,436,150 |
|
$ |
7 |
|
|
$ |
510,695 |
|
|
$ |
(328 |
) |
|
$ |
(291,986 |
) |
|
$ |
218,388 |
|
Vesting of common stock issued for early exercise of stock options |
|
- |
|
|
- |
|
|
|
3,908 |
|
|
- |
|
|
|
91 |
|
|
|
- |
|
|
|
- |
|
|
|
91 |
|
Issuance of common stock in connection with exercise of stock options |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Issuance of common stock in connection with vesting of restricted stock units |
|
- |
|
|
- |
|
|
|
4,726 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Issuance of common stock in connection with employee stock purchase plan |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
Stock-based compensation |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
2,794 |
|
|
|
- |
|
|
|
- |
|
|
|
2,794 |
|
Unrealized gain on available-for-sale securities |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
114 |
|
|
|
- |
|
|
|
114 |
|
Net loss |
|
- |
|
|
- |
|
|
|
- |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(22,360 |
) |
|
|
(22,360 |
) |
Balance at September 30, 2023 |
|
2,500 |
|
$ |
- |
|
|
|
2,444,784 |
|
$ |
7 |
|
|
$ |
513,580 |
|
|
$ |
(214 |
) |
|
$ |
(314,346 |
) |
|
$ |
199,027 |
|
See accompanying notes to these unaudited financial statements.
Singular Genomics Systems, Inc.
Statements of Cash Flows
(Unaudited)
(In thousands)
|
|
|
|
|
|
|
|
|
Nine Months Ended September 30, |
|
|
2024 |
|
|
2023 |
|
Operating activities |
|
|
|
|
|
Net loss |
$ |
(63,073 |
) |
|
$ |
(71,571 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
Stock-based compensation |
$ |
7,247 |
|
|
$ |
8,717 |
|
Depreciation |
|
3,152 |
|
|
|
2,533 |
|
Amortization of right-of-use lease assets |
|
2,041 |
|
|
|
3,036 |
|
Gain on lease modification |
|
(1,590 |
) |
|
|
- |
|
Accretion of discount on short-term investments |
|
(1,255 |
) |
|
|
(46 |
) |
Long-lived asset impairment |
|
182 |
|
|
|
1,900 |
|
Accretion of debt issuance costs |
|
119 |
|
|
|
110 |
|
Lease incentives received |
|
- |
|
|
|
1,840 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
Accounts receivable |
|
382 |
|
|
|
514 |
|
Inventory, net |
|
(1,622 |
) |
|
|
(940 |
) |
Prepaid expenses and other current assets |
|
575 |
|
|
|
312 |
|
Other noncurrent assets |
|
83 |
|
|
|
1,040 |
|
Accounts payable |
|
(147 |
) |
|
|
(1,314 |
) |
Accrued expenses |
|
(1,032 |
) |
|
|
370 |
|
Other current liabilities |
|
(340 |
) |
|
|
139 |
|
Lease liabilities |
|
(6,332 |
) |
|
|
(1,422 |
) |
Other noncurrent liabilities |
|
81 |
|
|
|
37 |
|
Net cash used in operating activities |
|
(61,529 |
) |
|
|
(54,745 |
) |
Investing activities |
|
|
|
|
|
Purchases of short-term investments |
|
(37,853 |
) |
|
|
(129,099 |
) |
Maturities of short-term investments |
|
135,553 |
|
|
|
122,846 |
|
Sales of short-term investments |
|
169 |
|
|
|
19,987 |
|
Purchases of property and equipment |
|
(33 |
) |
|
|
(578 |
) |
Net cash provided by investing activities |
|
97,836 |
|
|
|
13,156 |
|
Financing activities |
|
|
|
|
|
Proceeds from issuance of common stock under employee stock purchase plan |
|
80 |
|
|
|
624 |
|
Proceeds from issuance of common stock under equity incentive plans |
|
- |
|
|
|
13 |
|
Repurchases of common stock under equity incentive plans |
|
- |
|
|
|
(13 |
) |
Net cash provided by financing activities |
|
80 |
|
|
|
624 |
|
Net increase in cash and cash equivalents and restricted cash |
|
36,387 |
|
|
|
(40,965 |
) |
Cash and cash equivalents and restricted cash, beginning of year |
|
16,833 |
|
|
|
75,977 |
|
Cash and cash equivalents and restricted cash, end of year |
$ |
53,220 |
|
|
$ |
35,012 |
|
|
|
|
|
|
|
Supplemental disclosure for cash activities |
|
|
|
|
|
Interest paid |
$ |
821 |
|
|
$ |
777 |
|
Supplemental disclosure for non-cash activities |
|
|
|
|
|
Increase (decrease) in lease liability on lease modifications |
$ |
(14,729 |
) |
|
$ |
19,475 |
|
Inventory transferred to property and equipment |
$ |
1,643 |
|
|
$ |
6,498 |
|
Purchases of property and equipment included in accounts payable |
$ |
447 |
|
|
$ |
- |
|
Purchases of inventory included in accounts payable |
$ |
135 |
|
|
$ |
647 |
|
Vesting of common stock issued for early exercise of stock options |
$ |
65 |
|
|
$ |
300 |
|
See accompanying notes to these unaudited financial statements.
Singular Genomics Systems, Inc.
Notes to Financial Statements
(Unaudited)
1. Business
Description of Business
Singular Genomics Systems, Inc. (the “Company”) is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In addition, the Company is currently developing the G4X Spatial Sequencer, which will leverage the Company’s proprietary sequencing technology, applying it as an in situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company’s mission is to empower researchers and clinicians to advance science and medicine.
The Company was incorporated in the state of Delaware in June 2016 and has its principal operations in San Diego, California.
Liquidity and Capital Resources
The Company has incurred net losses since inception and, as of September 30, 2024 and December 31, 2023, had an accumulated deficit of $400.7 million and $337.6 million, respectively. The Company has a limited operating history, and the revenue and income potential of the Company’s business are unproven. From incorporation in June 2016 through September 30, 2024, substantially all of the Company’s operations have been funded by the sales of equity securities and issuances of debt. As of September 30, 2024, the Company had cash, cash equivalents and short-term investments of $113.8 million. The Company believes that its cash, cash equivalents and short-term investments as of September 30, 2024 are sufficient to fund its operations for at least 12 months from the issuance date of the accompanying unaudited financial statements.
2. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Use of Estimates
The accompanying unaudited financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures required by GAAP for annual financial statements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation, have been included. Interim financial results are not necessarily indicative of results anticipated for the full year.
The preparation of the Company’s unaudited financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited financial statements and accompanying notes. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may significantly differ from these estimates and assumptions. For the year ended December 31, 2023, significant estimates and assumptions include the value of lease liabilities and right-of-use lease assets. There were no changes to the Company's significant estimates and assumptions subsequent to December 31, 2023.
On June 25, 2024, the Company filed a certificate of amendment (the “Reverse Stock Split Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to effect a 1-for-30 reverse stock split of its common stock (the “Reverse Stock Split”), which became effective at 12:01 a.m. Eastern Time on June 26, 2024. The Reverse Stock Split Amendment does not reduce the number of authorized shares of common stock, which remains at 400,000,000, and does not change the par value of the common stock, which remains at $0.0001 per share. The Reverse Stock Split does not reduce the number of shares of the Company’s Series A Preferred Stock outstanding, which remains at 2,500 shares but is subject to a proportional conversion ratio adjustment. Additionally, the Company’s outstanding equity-based awards and other outstanding equity rights were proportionately adjusted. The Reverse Stock Split was effective for purposes of trading on the Nasdaq Capital Market as of the opening of business on June 26, 2024. Accordingly, all share and per share amounts of common stock for all periods presented in these unaudited financial statements and related notes have been retroactively adjusted to give effect to the Reverse Stock Split.
Summary of Significant Accounting Policies
During the nine months ended September 30, 2024, other than the policies described below, there were no changes to the Company’s significant accounting policies as described in Note 2 to the audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Cash, Cash Equivalents and Restricted Cash
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the balance sheets (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2024 |
|
|
2023 |
|
Cash and cash equivalents |
|
$ |
52,620 |
|
|
$ |
16,233 |
|
Restricted cash |
|
|
600 |
|
|
|
600 |
|
Total |
|
$ |
53,220 |
|
|
$ |
16,833 |
|
Short-term Investments
Short-term investments consisted of U.S. treasury securities at September 30, 2024 and U.S. treasury securities, corporate debt securities and asset-backed securities at December 31, 2023. The Company’s investments in securities are classified as current as they are available for use in current operations. The following tables summarize the short-term investments held by the Company at September 30, 2024 and December 31, 2023 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2024 |
|
|
Amortized
Cost |
|
|
Gross
Unrealized
Gains |
|
|
Estimated
Fair Value |
|
U.S. treasury securities |
$ |
61,130 |
|
|
$ |
83 |
|
|
$ |
61,213 |
|
Total |
$ |
61,130 |
|
|
$ |
83 |
|
|
$ |
61,213 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2023 |
|
|
Amortized
Cost |
|
|
Gross
Unrealized
Gains (Losses) |
|
|
Estimated
Fair Value |
|
U.S. treasury securities |
$ |
149,129 |
|
|
$ |
158 |
|
|
$ |
149,287 |
|
Corporate debt securities |
|
8,255 |
|
|
|
(3 |
) |
|
|
8,252 |
|
Asset-backed securities |
|
169 |
|
|
|
- |
|
|
|
169 |
|
Total |
$ |
157,553 |
|
|
$ |
155 |
|
|
$ |
157,708 |
|
The following table summarizes the estimated fair value of contractual maturities of available-for-sale debt securities held by the Company at September 30, 2024 and December 31, 2023 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, |
|
|
December 31, |
|
|
|
2024 |
|
|
2023 |
|
Due within one year |
|
$ |
61,213 |
|
|
$ |
157,540 |
|
Due after one but within five years |
|
|
- |
|
|